Ohio State Navbar


Matthew Ringel, MD

Staff photo

1581 Dodd Dr
Columbus, OH 43210


Current OSU Appointments

Professor, Endo, Diabetes & Metabolism

Professor, SBS-Molec Vir, Imm & Med Gen

Physician, FGP-Endo-Diabetes & Metabolism



OTHER EXPERTISE Reviewer for: Thyroid, Journal of Clinical Endocrinology and Metabolism, New England Journal of Medicine, Nature Medicine, Clinical Chemistries, Molecular Endocrinology, Endocrinology, Cancer Research, Molecular Cancer Research, Endocrine-Related Cancer, Biotechniques, Endocrine-Related Cancer, Clinical Cancer Research, Journal of Biological Chemistry. I have been or am currently on the following editorial boards: Endocrine Reviews, Thyroid (both current); and completed tenures on the editorial board for Endocrine-Related cancer and J Clinical Endocrinology and Metabolism. I have been an ad hoc reviewer for NIH study sections and for ARRA proposals for the past several years.

Chapters in Books

Leonard Wartofsky, Matthew D. Ringel, Kenneth D. Burman. "Therapy of Graves' Ophthalmopathy." In Graves' Disease: Pathogenesis and Treatment. first ed. Edited by Basil Rapoport and Sandra McLachlan. 257-278. Boston, MA: Kluwer Academic Publishers, January 2000.

Nikolaos Stathatos and Matthew D. Ringel. "Molecular Markers of Thyroid Nodules." In Thyroid Neoplasms. Edited by Bryan Haugen. 19-34. New York, NY: Elsevier BV, January 2005.

Matthew D. Ringel. "Additional Modalities for Treatment for Well-Differentiated Thyroid Cancer and Future Directions." In Thyroid Cancer: A Guide for Patients. second ed. Edited by Van Nostrand D; Wartofsky L, Bloom G, and Kularni KP. 309-320. Pasadena, MD: Keystone Press, Inc, January 2010.



2009 Samuel Haines Lectureship. Division of Endocrinology, Mayo Clinic.
2009 Farahe Maloof Lectureship. Division of Endocrinology Massachusetts General Hospital.
2009 Best Doctors in America.
2009 Van Meter Award. American Thyroid Association.
2010 Best Doctors in America.
2010 Excellence in Clinical Care Award.
2011 Best Doctors in America.
2011 Fellowship in American College of Physicians. American College of Physicians.

Journal Articles

Oertel, Yolanda, C; Burman, Kenneth; Boyle, Lisa; Ringel, Matthew; Wartofsky, Leonard; Shmookler, Barry; Yeganeh, Frederick; Van Nostrand, Douglas. "Integrating fine-needle aspiration into a daily practice involving thyroid disorders: the Washington Hospital Center approach.." Diagnostic cytopathology. Vol. 27, no. 2. (January 2002.): 120-2.

Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD. "AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.." Endocrinology. Vol. 146, no. 10. (October 2005.): 4456-.

Saji M; Vasko V; Kada F; Allbritton EH; Burman KD; Ringel MD. "Akt1 contains a functional leucine-rich nuclear export sequence.." Biochemical And Biophysical Research Communications. Vol. 332, no. 1. (June 2005.): 167-.

Acharyya S; Butchbach ME; Sahenk Z; Wang H; Saji M; Carathers M; Ringel MD; Skipworth RJ; Fearon KC; Hollingsworth MA; Muscarella P; Burghes AH; Rafael-Fortney JA; Guttridge DC. "Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia.." Cancer Cell. Vol. 8, no. 5. (November 2005.): 421-.

Harii, Norikazu; Lewis, Christopher, J; Vasko, Vasilly; McCall, Kelly; Benavides-Peralta, Uruguaysito; Sun, Xiaolu; Ringel, Matthew, D; Saji, Motoyasu; Giuliani, Cesidio; Napolitano, Giorgio; Goetz, Douglas, J; Kohn, Leonard D. "Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis.." Molecular endocrinology (Baltimore, Md.). Vol. 19, no. 5. (January 2005.): 1231-50.

Stathatos N; Bourdeau I; Espinosa AV; Saji M; Vasko VV; Burman KD; Stratakis CA; Ringel MD. "KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity.." The Journal Of Clinical Endocrinology And Metabolism. Vol. 90, no. 9. (September 2005.): 5432-.

Xing M; Westra WH; Tufano RP; Cohen Y; Rosenbaum E; Rhoden KJ; Carson KA; Vasko V; Larin A; Tallini G; Tolaney S; Holt EH; Hui P; Umbricht CB; Basaria S; Ewertz M; Tufaro AP; Califano JA; Ringel MD; Zeiger MA; Sidransky D; Ladenson PW. "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.." The Journal Of Clinical Endocrinology And Metabolism. Vol. 90, no. 12. (December 2005.): 6373-.

Mrozek E; Kloos RT; Ringel MD; Kresty L; Snider P; Arbogast D; Kies M; Munden R; Busaidy N; Klein MJ; Sherman SI; Shah MH. "Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.." The Journal Of Clinical Endocrinology And Metabolism. Vol. 91, no. 6. (June 2006.): 2201-.

Yang CC; Ku CY; Wei S; Shiau CW; Chen CS; Pinzone JJ; Ringel MD; Chen CS. "Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells.." Molecular Pharmacology. Vol. 69, no. 5. (May 2006.): 1564-.

Pinzone JJ; Eng C; Paik J; Brindle KA; Ringel MD; Katz JD. "A novel PTEN mutation in Cowden syndrome is associated with a mixed degenerative-erosive arthritic process: potential molecular pathogenic mechanisms.." American Journal Of Medical Genetics. Part A. Vol. 143A, no. 13. (July 2007.): 1522-.

Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD. "2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.." Molecular Pharmacology. Vol. 72, no. 5. (November 2007.): 1124-.

(March 2007.): 942-.

Mody M; Dharker N; Bloomston M; Wang PS; Chou FS; Glickman TS; McCaffrey T; Yang Z; Pumfery A; Lee D; Ringel MD; Pinzone JJ. "Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202.." Endocrine-Related Cancer. Vol. 14, no. 2. (June 2007.): 305-.

(January 2007.): 16-.

Ringel MD. "Can ultrasound and clinical features be used to predict thyroid cancer in solitary nodules and multinodular goiter?." Nature Clinical Practice. Endocrinology & Metabolism. Vol. 3, no. 4. (April 2007.): 334-.

Agrawal A; Hall NC; Ringel MD; Povoski SP; Martin EW Jr. "Combined use of perioperative TSH-stimulated (18)F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma.." The Laryngoscope. Vol. 118, no. 12. (December 2008.): 2190-.

Paes JE; Ringel MD. "Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.." Endocrinology And Metabolism Clinics Of North America. Vol. 37, no. 2. (June 2008.): 375-.

Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH. "Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.." The Journal Of Clinical Endocrinology And Metabolism. Vol. 94, no. 1. (January 2009.): 164-.

Espinosa AV; Shinohara M; Porchia LM; Chung YJ; McCarty S; Saji M; Ringel MD. "Regulator of calcineurin 1 modulates cancer cell migration in vitro.." Clinical & Experimental Metastasis. Vol. 26, no. 6. (January 2009.): 517-.

Sipos JA; Ringel MD. "Do tumor characteristics predict risk of malignancy in thyroid nodules with indeterminate cytology?." Nature Clinical Practice. Endocrinology & Metabolism. Vol. 5, no. 3. (March 2009.): 140-.

Jazdzewski K; Liyanarachchi S; Swierniak M; Pachucki J; Ringel MD; Jarzab B; de la Chapelle A. "Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer.." Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 106, no. 5. (February 2009.): 1502-.

Kloos RT*; Ringel MD*; Knopp MV; Hall NC; King M; Stevens R; Liang J; Wakely PE Jr; Vasko VV; Saji M; Rittenberry J; Wei L; Arbogast D; Collamore M; Wright JJ; Grever M; Shah MH. "Phase II trial of sorafenib in metastatic thyroid cancer.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 27, no. 10. (April 2009.): 1675-.

Nadella KS; Saji M; Jacob NK; Pavel E; Ringel MD; Kirschner LS. "Regulation of actin function by protein kinase A-mediated phosphorylation of Limk1.." EMBO Reports. Vol. 10, no. 6. (June 2009.): 599-.

Kloos RT; Eng C; Evans DB; Francis GL; Gagel RF; Gharib H; Moley JF; Pacini F; Ringel MD; Schlumberger M; Wells SA Jr. "Medullary thyroid cancer: management guidelines of the American Thyroid Association.." Thyroid: Official Journal Of The American Thyroid Association. Vol. 19, no. 6. (June 2009.): 565-.

Ringel MD. "Molecular markers of aggressiveness of thyroid cancer.." Current Opinion In Endocrinology, Diabetes, And Obesity. Vol. 16, no. 5. (October 2009.): 361-.

Cheng SY; Ringel MD. "Frontiers in thyroid cancer: December 2009.." Thyroid: Official Journal Of The American Thyroid Association. Vol. 19, no. 12. (December 2009.): 1297-.

Paes JE; Hua K; Nagy R; Kloos RT; Jarjoura D; Ringel MD. "The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study.." The Journal Of Clinical Endocrinology And Metabolism. Vol. 95, no. 9. (September 2010.): 4244-.

Al-Saif O; Farrar WB; Bloomston M; Porter K; Ringel MD; Kloos RT. "Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer.." The Journal Of Clinical Endocrinology And Metabolism. Vol. 95, no. 5. (May 2010.): 2187-.

Saji M; Ringel MD. "The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.." Molecular And Cellular Endocrinology. Vol. 321, no. 1. (May 2010.): 20-.

Lam ET; Ringel MD; Kloos RT; Prior TW; Knopp MV; Liang J; Sammet S; Hall NC; Wakely PE Jr; Vasko VV; Saji M; Snyder PJ; Wei L; Arbogast D; Collamore M; Wright JJ; Moley JF; Villalona-Calero MA; Shah MH. "Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 28, no. 14. (May 2010.): 2323-.

McCarty SK; Saji M; Zhang X; Jarjoura D; Fusco A; Vasko VV; Ringel MD. "Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.." Endocrine-Related Cancer. Vol. 17, no. 4. (October 2010.): 989-.

You J; Wang L; Saji M; Olesik SV; Ringel MD; Lucas DM; Byrd JC; Freitas MA. "High-sensitivity TFA-free LC-MS for profiling histones.." Proteomics. Vol. 11, no. 16. (August 2011.): 3326-.

Nagy R; Ganapathi S; Comeras I; Peterson C; Orloff M; Porter K; Eng C; Ringel MD; Kloos RT. "Frequency of germline PTEN mutations in differentiated thyroid cancer.." Thyroid: Official Journal Of The American Thyroid Association. Vol. 21, no. 5. (May 2011.): 505-.

Ringel MD. "Linking oncogenes to invasion in thyroid cancer.." Cell Cycle (Georgetown, Tex.). Vol. 10, no. 5. (March 2011.): 737-.

Ringel MD. "Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.." Thyroid: Official Journal Of The American Thyroid Association. Vol. 21, no. 5. (May 2011.): 487-.

Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng S-Y, Ringel MD.. "Akt1 deficiency delays tumor progression and vascular invasion and prevents distant metastasis is a murine model of thyroid cancer.." Oncogene. (January 2011.): -.

Arab K, Smith LT, Gast A, Weichenhan D, Huang J, Claus R, Hielscher T, Espinosa AV, Ringel MD, Morrison CD, Schadendorf D, Kumar R, Plass C.. "Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma.." Carcinogenesis. (January 2011.): -.

Bekaii-Saab T; Phelps MA; Li X; Saji M; Goff L; Kauh JS; O'Neil BH; Balsom S; Balint C; Liersemann R; Vasko VV; Bloomston M; Marsh W; Doyle LA; Ellison G; Grever M; Ringel MD; Villalona-Calero MA. "Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 29, no. 17. (June 2011.): 2357-.



"Metastasis suppression in thyroid cancer." Presented at Endocrine Society Annual Meeting, Washington, DC. (January 2007)

"PI3K singaling in thyroid cancer." Presented at American Thyroid Association Annual Meeting, . (January 2008)

"Management of Progressive Thyroid Cancer." Presented at Medical Grand Rounds, DaeJoon. (January 2008)

"Akt in Thyroid Cancer." Presented at Korean Endocrine Society, Seoul. (January 2008)

"Van Meter Award Lecture." Presented at Amerian Thyroid Association Annual Meeting, Palm Beach, FL. (January 2009)

"Management of Progressive Thyroid Cancer." Presented at American Thyroid Association Thyroid Cancer Meeting, Miami, FL. (January 2009)

"Practical Application of Thyroid Cancer Guidelines." Presented at Ohio Valley Regional AACE Meeting, Indianapolis, IN. (January 2010)

"PI3 Kinase in Thyroid Cancer." Presented at International Thyroid Congress, Paris, FR|FRA. (January 2010)

"Akt in thyroid cancer progression." Presented at International Congress of Endocrinology, Kyoto, JP|JPN. (January 2010)